山东赛托生物科技股份有限公司 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 4 月 25 日刊登在中国证监会指定的创业板信息披露网站巨潮 资讯网。为了让广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 5 日（星期五）15:00-17:00 在"全景网"和"价值在线"双平台采用网 络互动的方式举办 2022 年年度业绩说明会，投资者可根据习惯和方便选择登陆 "全景•路演天下"（http://rs.p5w.net）和"价值在线"（www.ir-online.cn） 任一平台参与本次年度业绩说明会。 证券代码：300583 证券简称：赛托生物 编号：2023-030 （全景•路演天下问题征集页面二维码） （价值在线问题征集页面小程序） 敬请广大投资者提前提交您所关注的问题，便于公司在业绩说明会上对投资 者普遍关注的问题进行回答，提升此次业绩说明会的针对性。 欢迎广大投资者积极参与本次网上说 ...

山东赛托生物科技股份有限公司 2022 年第三季度报告 证券代码：300583 证券简称：赛托生物 公告编号：2022-077 山东赛托生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 山东赛托生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 296,709,591.90 | 14.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 636,242,960.65, representing a 2.03% increase compared to CNY 623,607,764.69 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 32,339,106.58, a significant increase of 70.17% from CNY 19,003,606.57 in the previous year[23]. - The net profit after deducting non-recurring gains and losses reached CNY 30,750,102.42, marking a 376.30% increase compared to CNY 6,456,016.31 in the same period last year[23]. - Cash flow from operating activities surged to CNY 182,721,185.87, a remarkable increase of 2,024.10% from CNY 8,602,296.58 in the previous year[24]. - Basic earnings per share rose to CNY 0.30, up 66.67% from CNY 0.18 in the same period last year[24]. - Total assets at the end of the reporting period were CNY 3,219,475,133.82, an increase of 8.41% from CNY 2,969,699,298.75 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 1,712,375,060.99, reflecting a 1.76% increase from CNY 1,682,729,774.58 at the end of the previous year[24]. - The weighted average return on net assets was 1.90%, an increase of 0.75% compared to 1.15% in the previous year[24]. Investment and Projects - The company has invested ¥35,998.80 million in the project for an annual production of 700 tons of 9-hydroxyandrostenedione, and ¥23,475.55 million in the steroid intermediates and raw materials project[78]. - The company has adjusted the investment plan, terminating the construction of the 120 tons of 4-ene and 180 tons of dihydroxyprogesterone production lines, focusing on the 700 tons of 9-hydroxyandrostenedione production line[79]. - The company has allocated ¥27,000.00 million of repurposed funds to a new project for steroid intermediates and raw materials, with a total investment of ¥45,091.00 million[79]. - The company has used ¥11,460.00 million of repurposed funds to acquire 100% equity of Runxin Thermal Power[80]. - The annual net profit expected from the "700 tons of 9-hydroxyandrostenedione, 120 tons of 4-androstenedione, and 180 tons of hydroxyprogesterone project" was originally estimated at CNY 472.17 million, but after adjustments, the average annual net profit is now projected to be CNY 159.39 million[84]. - The "steroid intermediates and raw materials project" has completed the construction of three workshops, two warehouses, and a control center, but is still pending some equipment installation due to pandemic-related delays[84]. - The completion deadline for the "steroid intermediates and raw materials project" has been extended to May 1, 2023, with partial construction completed as of June 30, 2022[84]. Subsidiaries and Equity - The subsidiary Disen Bio reported a net profit of CNY 19.85 million, contributing significantly to the company's overall performance[95]. - The subsidiary Sry Pharmaceutical achieved a net profit of CNY 8.99 million, reflecting its role in the company's profitability[95]. - The company holds 100% equity in Disen Bio and 85% in Sry Pharmaceutical, indicating strong control over its key subsidiaries[97][98]. Environmental and Social Responsibility - The company is committed to environmental protection and has invested in reducing pollution during production processes[108]. - The company emphasizes its commitment to environmental protection and sustainable development, focusing on resource efficiency and waste management[148]. - The company actively engages in social responsibility initiatives, contributing to community management and public welfare[147]. - Environmental monitoring is conducted regularly by third parties, with results publicly disclosed[143]. - The company has established an emergency response plan for environmental incidents, which has been filed with local authorities[142]. Share Capital and Stock Management - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the cancellation of 330,500 restricted stocks due to unmet performance targets, reducing the total share capital from 107,252,567 shares to 106,922,067 shares[22]. - The company has implemented a stock incentive plan to enhance the responsibility and mission of its management team[116]. - The stock incentive plan was approved in 2017, granting 1.322 million shares to 47 incentive targets[118]. - The company completed a wastewater treatment facility with a capacity of 4,000 m³/d in June 2016 and another with a capacity of 3,600 m³/d in February 2021[133]. Financial Management and Compliance - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[90][91][92]. - The company has not sold any major assets during the reporting period, maintaining its asset base[93]. - The company has maintained transparency in information disclosure, adhering to legal and regulatory requirements[149]. - The company borrowed a total of 9,000,000 RMB from its controlling shareholder, with an interest rate of 7.00%, resulting in an interest expense of 132.42 million RMB for the period[165]. - The financial report for the first half of 2022 was not audited[195].

重要内容提示: 山东赛托生物科技股份有限公司 2022 年第一季度报告全文 证券代码：300583 证券简称：赛托生物 公告编号:2022-021 山东赛托生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 253,646,857.08 | 272,376,194.52 | -6.88% | | 归属于上市公司股东的净利润（元） | 12,739,9 ...

Financial Performance - The company's operating revenue for 2021 was CNY 1,202,622,703.68, representing a 31.70% increase compared to CNY 913,187,604.30 in 2020[25]. - The net profit attributable to shareholders for 2021 was CNY 36,205,360.05, a significant turnaround from a loss of CNY 179,807,242.83 in 2020, marking a 120.14% improvement[25]. - The basic earnings per share for 2021 was CNY 0.34, compared to a loss of CNY 1.68 per share in 2020, reflecting a 120.24% increase[25]. - The company achieved a revenue of 1,202.87 million yuan and a net profit of 36.21 million yuan, representing a year-on-year growth of 120.14%[62]. - The total operating revenue for 2021 was CNY 1,202.62 million, representing a 31.70% increase compared to CNY 913.19 million in 2020[72]. - The pharmaceutical manufacturing segment accounted for 97.04% of total revenue, with a year-on-year growth of 32.71%[75]. - The sales volume of steroid drug raw materials increased by 35.33% year-on-year, reaching CNY 1,063.10 million[75]. - The company achieved a gross margin of 22.82% in the pharmaceutical manufacturing sector, an increase of 10.63% compared to the previous year[75]. - The company reported a total revenue of 3,594 million CNY for the year 2021[160]. Investment and R&D - The company plans to increase R&D investment to maintain its technological leadership in the industry, while implementing strict confidentiality measures to protect core technologies[9]. - The company has invested over 200 million yuan in R&D, resulting in 42 patents, including 14 invention patents[57]. - R&D expenses reached CNY 49,730,559.44, a 10.49% increase compared to CNY 45,007,850.59 in 2020[84]. - The company is actively working on the registration and production of new high-end specialty APIs, positioning itself for future growth[64]. - The company aims to transition from intermediates to high-end specialty APIs and finished formulations, enhancing its competitive edge in the pharmaceutical sector[131]. - The company plans to increase R&D investment in 2022 to drive innovation and address industry challenges, emphasizing collaboration with key universities and research institutions[137]. Market and Product Strategy - The company aims to enhance its product structure and expand the production scale of high-end intermediates, focusing on respiratory high-end specialty raw materials[12]. - The company is committed to adjusting its product structure and improving the technical content and added value of its products through lean management and technological innovation[12]. - The company is focused on strengthening cooperation with existing customers while actively seeking new clients to ensure sustainable development[7]. - The company is positioned to cover the entire industry chain from intermediates to raw materials and formulations, enhancing its competitive advantage[41]. - The market for assisted reproductive drugs is expanding due to changing national population and fertility policies, presenting significant opportunities[36]. - The company is positioned to become a global production center for steroid hormone raw materials, with domestic production accounting for approximately one-third of the world's total output[35]. Operational Efficiency and Management - The company will optimize its organizational structure and enhance management capabilities to mitigate management risks associated with its accelerated growth[8]. - The company has implemented measures to enhance management efficiency and reduce costs, resulting in significant improvements in production quality and efficiency[67]. - The company has established a competitive R&D and production system for respiratory high-end specialty APIs, with several products ready for mass production[64]. - The company has established stable strategic partnerships with leading pharmaceutical companies, enhancing brand recognition in the industry[59]. - The company has implemented a comprehensive management optimization strategy to improve efficiency and reduce costs[50]. Environmental Commitment - The company emphasizes environmental protection and has implemented measures to reduce pollution and waste emissions in its production processes[11]. - The company is committed to environmental protection and aims to achieve zero environmental pollution incidents while enhancing its green production capabilities[136]. Risks and Challenges - The company is facing industry risks due to increasing competition and rising costs of raw materials, which may impact its performance[6]. - The company acknowledges the risk of investment project failures if market expansion is insufficient, and plans to actively explore markets to absorb new production capacity[12]. - Management risks are anticipated as the company expands its business scope, necessitating optimization of organizational structure and talent management[140]. - The pharmaceutical industry is undergoing significant transformation, with increasing regulatory standards and market consolidation, presenting both challenges and opportunities for the company[35]. Governance and Shareholder Relations - The company has a board of directors consisting of 7 members, including 3 independent directors, which complies with legal and regulatory requirements[149]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to enhance investor relations[153]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, during voting processes[148]. - The company has not engaged in any related party transactions that could harm the interests of shareholders[157]. - The company has maintained a rigorous approach to governance, adhering to laws and regulations throughout its operations[178]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 1,140, with 739 in production, 182 in technical roles, and 21 in sales[184]. - The company has implemented a performance-based compensation system, aligning employee salaries with market standards and company performance[185]. - A systematic employee training plan was established to enhance employee skills and overall company competitiveness, including various training programs[186]. - The total remuneration for the board of directors, supervisors, and senior management in 2021 amounted to 4.2615 million RMB[171]. Future Outlook - The financial outlook for the upcoming year remains positive, with expectations for continued growth in revenue and market share[165]. - Future growth opportunities are anticipated in the advanced manufacturing sector of pharmaceuticals, particularly in raw materials and high-quality generics[130].

Financial Performance - Revenue for Q3 2021 reached ¥258,468,655.81, an increase of 11.37% year-over-year, and total revenue for the year-to-date was ¥882,076,420.50, up 21.66% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥12,578,394.22, representing a significant increase of 204.17% year-over-year, with year-to-date net profit at ¥31,582,000.79, up 164.29%[3] - The basic earnings per share for Q3 2021 was ¥0.1178, an increase of 204.34% year-over-year, while the diluted earnings per share also stood at ¥0.1178, up 205.56%[3] - Total operating revenue for Q3 2021 reached CNY 882,076,420.50, an increase of 21.7% compared to CNY 725,008,466.40 in the same period last year[21] - Net profit for Q3 2021 was CNY 30,207,464.49, a significant recovery from a net loss of CNY 59,283,354.55 in the previous year[22] - Earnings per share for Q3 2021 were CNY 0.2978, compared to a loss per share of CNY 0.4595 in the same quarter last year[23] - The company reported a total comprehensive income of CNY 32,562,901.09 for Q3 2021, recovering from a loss of CNY 59,283,354.55 in the previous year[23] Assets and Liabilities - Total assets as of the end of Q3 2021 were ¥3,048,613,279.71, reflecting a growth of 7.30% from the end of the previous year[3] - The company's total assets increased to CNY 3,048,613,279.71, up from CNY 2,841,295,244.66 year-over-year[19] - Total liabilities rose to CNY 1,324,660,962.86, compared to CNY 1,149,916,239.64 in the previous year, indicating a year-over-year increase of 15.2%[19] - The company's equity attributable to shareholders increased to CNY 1,676,693,530.56, up from CNY 1,643,008,784.70[19] - The company’s total equity attributable to shareholders was ¥1,676,693,530.56, a slight increase of 2.05% from the end of the previous year[3] Cash Flow - The company reported a net cash flow from operating activities of ¥34,619,403.71 year-to-date, which is a decrease of 86.45% compared to the same period last year[3] - The net cash flow from operating activities was 34,619,403.71, a decrease of 86.4% compared to 255,467,635.44 in the previous period[26] - Cash inflow from operating activities totaled 650,380,676.22, down 6.9% from 698,176,828.78 in the previous period[26] - Cash outflow from operating activities increased to 615,761,272.51, up 39.0% from 442,709,193.34 in the previous period[26] - The net cash flow from investing activities was -270,485,660.90, worsening from -123,559,294.95 in the previous period[26] - Cash inflow from financing activities was 468,772,392.51, an increase of 15.7% compared to 405,000,000.00 in the previous period[26] - The net cash flow from financing activities improved to 52,683,921.28, compared to -134,660,452.16 in the previous period[26] - The total cash and cash equivalents at the end of the period was 60,765,676.58, down from 157,087,291.42 in the previous period[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,062[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[11] - The second-largest shareholder, Mi Chaojie, holds 22.79% of shares, totaling 24,448,000 shares[11] Research and Development - Research and development expenses for the year-to-date increased to ¥3,414.07 million, a rise of 36.26% compared to the same period last year, driven by increased project activity[9] - Research and development expenses for Q3 2021 were CNY 34,140,716.76, compared to CNY 25,054,992.89 in the same period last year, marking a 36.3% increase[22] Tax and Other Liabilities - The company reported a significant increase in tax liabilities, with amounts due rising by 241.02% year-over-year to ¥1,064.59 million, reflecting increased business activity[9] - The company received 4,194,489.51 in tax refunds, significantly up from 994,103.21 in the previous period[26] Inventory and Receivables - The company’s accounts receivable increased by 96.40% year-over-year to ¥19,803.34 million, attributed to higher business volume[8] - Accounts receivable increased to ¥198,033,437.81 from ¥100,833,276.47 year-over-year[17] - Inventory as of September 30, 2021, is ¥533,188,364.38, slightly up from ¥532,404,151.77 at the end of 2020[17] Company Plans and Approvals - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission[13] - The company is actively engaging with intermediaries to address inquiries related to the A-share issuance process[14] Reporting and Audit - The company has not undergone an audit for the third quarter report[31] - The report was issued by the board of directors on October 29, 2021[32]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥623.61 million, representing a 26.51% increase compared to ¥492.92 million in the same period last year[24]. - The net profit attributable to shareholders of the listed company reached approximately ¥19.00 million, a significant turnaround from a loss of ¥37.05 million in the previous year, marking a 151.29% improvement[24]. - The basic earnings per share increased to ¥0.18, compared to a loss of ¥0.35 per share in the previous year, reflecting a 151.43% improvement[24]. - The company achieved a revenue of 623.61 million yuan, representing a year-on-year growth of 26.51%[39]. - The net profit attributable to shareholders reached 19.00 million yuan, marking a significant increase of 151.29% compared to the previous year[39]. - The total operating revenue for the first half of 2021 reached CNY 623,607,764.69, an increase of 26.5% compared to CNY 492,919,460.37 in the first half of 2020[184]. - The net profit for the first half of 2021 was CNY 67,555,080.43, a significant increase from CNY 21,881,079.93 in the first half of 2020, representing a growth of 208.5%[188]. Cash Flow and Assets - The net cash flow from operating activities was approximately ¥8.60 million, a decrease of 95.32% compared to ¥183.64 million in the same period last year[24]. - The company's operating cash flow net amount decreased by 95.32% to ¥8.60 million, primarily due to increased cash outflow from operating activities[55]. - Cash and cash equivalents at the end of the reporting period were ¥385.43 million, accounting for 11.87% of total assets, down from 12.12% the previous year[59]. - The cash flow from financing activities showed a net inflow of 104,197,506.47 CNY, compared to a net outflow of -25,375,430.85 CNY in the first half of 2020[195]. - The total cash inflow from operating activities was 253,436,604.83 CNY, slightly up from 237,133,002.07 CNY in the previous year[194]. - The total assets at the end of the reporting period amounted to 1,711.00 million RMB, compared to 1,664.16 million RMB at the end of the previous period, indicating a growth of approximately 2.82%[200]. Investments and R&D - Research and development expenses amounted to 25.71 million yuan, accounting for 4.12% of the total revenue, maintaining a high investment level[39]. - Research and development investment increased by 52.80% to ¥25.71 million from ¥16.82 million, driven by accelerated project progress[55]. - The company plans to increase R&D investment to accelerate the development and registration of new products[95]. - The company is focused on integrating the entire industry chain from intermediates to raw materials and finished formulations, enhancing its market position[48]. Market and Competitive Position - The company has established long-term and stable partnerships with leading enterprises in the steroid drug industry, enhancing its competitive position[45]. - The company is transitioning from a single steroid raw material supplier to a comprehensive biotechnology enterprise[36]. - China's pharmaceutical market is projected to continue growing, driven by increasing health awareness and an aging population[40]. - The company is focused on becoming a full-chain biotechnology enterprise, integrating intermediates, active pharmaceutical ingredients, and formulations[95]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a significant focus on environmental compliance[117]. - The company has signed a wastewater treatment service agreement with a local water utility, ensuring compliance with wastewater discharge standards[117]. - The company has implemented measures to monitor and control emissions of various pollutants, including ammonia nitrogen and hydrogen sulfide, ensuring compliance with environmental regulations[117]. - The wastewater treatment system has been upgraded, combining two systems to enhance treatment capacity[119]. Corporate Governance and Shareholder Information - The company has not distributed cash dividends or bonus shares for the half-year period[104]. - The company has established a stock incentive plan to enhance the motivation of its management and key technical personnel[105]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 37.11% of shares, totaling 39,802,720 shares[163]. - The company has maintained compliance with information disclosure regulations to protect the rights of minority shareholders[129]. Risk Management - The company has identified several risks, including national policy and industry risks, and has detailed these in the report[7]. - The company faces risks from industry competition and potential price fluctuations in steroid raw materials[94]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period, maintaining a conservative financial strategy[84][85].

Financial Performance - The company's revenue for Q1 2021 was CNY 272,376,194.52, representing a 22.60% increase compared to CNY 222,171,115.42 in the same period last year[8] - The net profit attributable to shareholders was a loss of CNY 5,371,348.90, an improvement of 77.84% from a loss of CNY 24,243,112.96 in the previous year[8] - The basic earnings per share were CNY -0.05, improving by 77.27% from CNY -0.22 in the same period last year[8] - The net profit attributable to shareholders was -5.37 million yuan, an increase of 77.84% year-on-year[26] - The net loss for Q1 2021 was CNY 4,955,375.78, a significant improvement from a net loss of CNY 29,031,607.96 in Q1 2020[51] - The company reported a total comprehensive income of CNY 17,798,306.66 for Q1 2021, compared to CNY 5,255,268.42 in Q1 2020, marking an increase of 237.5%[55] Cash Flow - The net cash flow from operating activities was negative at CNY -57,991,155.87, a decline of 843.09% compared to a positive cash flow of CNY 7,804,016.99 in the same period last year[8] - Cash received from operating activities decreased by 843.09%, resulting in a net cash flow of -57.99 million yuan[25] - The total cash flow from operating activities was negative CNY 57,991,155.87, a decline from a positive cash flow of CNY 7,804,016.99 in the same period last year[58] - The net cash flow from operating activities was ¥55,397,320.47, a decrease of 18% compared to ¥67,688,413.19 in the previous period[60] - Total cash inflow from operating activities amounted to ¥151,868,773.20, up 50% from ¥101,222,822.50 in the prior period[60] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,011,234,104.57, an increase of 5.98% from CNY 2,841,295,244.66 at the end of the previous year[8] - The total current asset of RMB 1.22 billion, up from RMB 1.14 billion, indicating an increase of about 6.9%[41] - The company's total liabilities reached CNY 1,326,112,564.91, compared to CNY 1,149,916,239.64 in the previous year, marking an increase of 15.4%[45] - The company's total liabilities increased to RMB 1.06 billion from RMB 944.00 million, reflecting an increase of about 12.5%[42] Shareholder Information - The company had a total of 12,222 preferred shareholders at the end of the reporting period[12] - The top ten shareholders held a significant portion of the company's shares, with the largest shareholder holding 39,802,720 shares, representing 37.11% of the total[12] - The total equity attributable to shareholders was CNY 1,637,637,435.80, slightly down from CNY 1,643,008,784.70, a decrease of 0.3%[45] Research and Development - R&D expenses increased by 52.60% to ¥11,286,267.83 as a result of accelerated project development[22] - Research and development expenses for Q1 2021 were CNY 11,286,267.83, an increase of 52.5% from CNY 7,395,918.08 in Q1 2020[51] Government Subsidies - The company received government subsidies amounting to CNY 2,811,471.50 during the reporting period[9] - Other income surged by 129.36% to ¥2,811,471.50 due to increased government subsidies related to operating activities[22] Investment Activities - The company invested 112.10 million yuan in fixed assets and intangible assets, a 94.96% increase compared to the previous year[25] - The company raised CNY 130,000,000.00 through financing activities, an increase from CNY 105,000,000.00 in the previous year[59] Operational Efficiency - The company plans to continue expanding its market presence and investing in R&D for new product development[18] - The company has achieved a production efficiency of 56.28% in its raw material drug project as of May 1, 2022[32] Market and Project Updates - The company is advancing the registration and certification of multiple drugs in the US, domestic, and EU markets, with no significant changes in project feasibility[32] - The company is facing increased external uncertainties and trade protectionism, which may impact project timelines and expected returns[32]

Financial Performance - The company's net profit attributable to shareholders was -179,807,242.83 RMB, a decrease of 425.09% compared to the previous year[6]. - The company's revenue for 2020 was ¥913,187,604.30, a decrease of 5.45% compared to ¥965,800,380.65 in 2019[27]. - The net profit attributable to shareholders was -¥179,807,242.83, representing a decline of 425.09% from a profit of ¥55,309,472.92 in 2019[27]. - The company's basic earnings per share for 2020 was -¥1.68, a decrease of 423.08% from ¥0.52 in 2019[27]. - The weighted average return on equity was -10.31% in 2020, a decline of 13.35% compared to 3.04% in 2019[27]. - The company reported a total of ¥890,079,289.25 in revenue after deducting non-main business income for 2020[28]. - The company reported a total revenue of 327,621,730 for the period, with a net loss of 32,917,769[118]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 341.89% to ¥254,600,648.67 from ¥57,616,516.66 in 2019[27]. - The company experienced a significant increase in cash flow from operating activities in Q2 2020, reaching ¥175,833,629.63[30]. - The net cash flow from investing activities decreased by 321.91% to -¥29,228,833.40, mainly due to increased project construction payments[85]. - The net cash flow from financing activities decreased by 1,667.27% to -¥140,732,755.48, as loan repayments exceeded new loans during the period[86]. - The company reported a significant increase in finished drug sales, which rose by 277.34% to ¥93,788,143.41[69]. - The company has achieved a cumulative investment progress of 66.24% in its fundraising projects[104]. Strategic Focus and Market Position - The company is focusing on becoming a biotechnology enterprise integrating "pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations" as part of its long-term strategy[6]. - The company plans to increase investment in high-end specialty raw materials and expand its overseas market presence, particularly through its subsidiary Lisapharma[12]. - The company has established a strategic layout in the respiratory high-end specialty raw materials and formulation products, enhancing its market competitiveness[41]. - The global steroid hormone drug market has been growing at over 10% annually, with a market size exceeding $150 billion in 2020, indicating strong demand for steroid intermediates and raw materials[42]. - The company has successfully entered the formulation field through the acquisition of Lisapharma, establishing a full industry chain from intermediates to raw materials and formulations[44]. - The company aims to upgrade its industry strategy, focusing on high-end specialty raw materials and finished formulations[128]. Operational Challenges and Risks - The company faces industry risks due to increased competition and potential fluctuations in raw material and labor costs[10]. - The ongoing global pandemic may impact the company's business revenue and operational performance, particularly affecting Lisapharma[13]. - The company is actively adjusting its operational strategies to mitigate the adverse effects of the pandemic on its business[13]. - The company has maintained a strong market position in the steroid drug raw material sector despite increased competition and a significant sales decline in Q2 2020[58]. Environmental and Social Responsibility - The company is committed to environmental protection and will continue to improve production processes to reduce waste emissions[15]. - The company has maintained a high standard in environmental management and aims for zero accidents in production safety[133]. - The company actively engages in environmental protection, implementing effective waste management and promoting clean production practices[189]. - During the reporting period, the company donated a total of 250,000 to various charitable organizations and provided over 700,000 in pandemic prevention materials[190]. Governance and Compliance - The company has established a governance structure to enhance the responsibility and mission of senior management and core technical personnel[158]. - The company has fulfilled its commitments regarding the accuracy and completeness of information disclosure related to its stock incentive plan[149]. - The company has maintained a continuous audit relationship with Tianjian Accounting Firm for 9 years, with the current auditors having served for 1 year and 3 years respectively[153]. - There were no major lawsuits or arbitration matters during the reporting period[155]. Research and Development - The company focuses on the production of steroid drug raw materials using genetic engineering and microbial transformation technologies, positioning itself as a key supplier in China[36]. - The company has made significant progress in the research and development of respiratory high-end specialty raw materials, completing domestic registration for several products[59]. - The number of R&D personnel increased to 172, representing 15.49% of the workforce, reflecting a commitment to enhancing R&D capabilities[83]. - R&D investment focused on high-end specialty raw materials, with ongoing projects like Fluticasone propionate[80]. Shareholder Relations and Returns - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[16]. - The cash dividend total for 2020 was 0.00 yuan, representing 0.00% of the total profit distribution[138]. - The company emphasizes shareholder returns while actively fulfilling responsibilities to employees, customers, and society, aiming for sustainable development[184]. - The company has committed to ensuring that the increase in cash dividend amount will at least match the growth rate of net profit if the net profit continues to grow steadily[148].

Financial Performance - Operating revenue for the reporting period was CNY 232,089,006.03, an increase of 12.12% year-on-year[9] - Net profit attributable to shareholders was a loss of CNY 12,075,333.32, a decrease of 161.01% compared to the same period last year[9] - Basic earnings per share were -CNY 0.1129, a decrease of 160.99% compared to the same period last year[9] - The company expects a full-year loss of CNY 40 million due to the impact of the pandemic on its subsidiary Lisapharma in Italy[26] - The net profit for Q3 2020 was a loss of CNY 13,548,149.68, compared to a profit of CNY 19,292,580.06 in the same period last year[45] - The company's operating revenue for the current period is $116.21 million, a decrease of 36.8% compared to $183.70 million in the previous period[48] - Operating profit for the current period is $4.66 million, down 87.5% from $37.17 million in the previous period[48] - Net profit for the current period is $3.21 million, a decline of 90.1% compared to $32.20 million in the previous period[49] - The total comprehensive income for the current period is -$59.28 million, compared to $82.43 million in the previous period[54] - Basic earnings per share for the current period is -$0.4595, compared to $0.7779 in the previous period[54] Cash Flow - Net cash flow from operating activities was CNY 71,829,988.82, an increase of 41.41% year-on-year[9] - The company reported a significant increase in cash flow from operating activities, with a year-to-date increase of 216.46%[9] - The net cash flow from operating activities increased by 216.46% to CNY 255,467,635.44, driven by enhanced collection efforts on accounts receivable[23] - The cash flow from operating activities was not detailed in the provided documents, indicating a need for further analysis on liquidity[46] - The company's total cash inflow from operating activities is ¥698,176,828.78, compared to ¥564,446,033.28 in the previous period, reflecting a positive trend[59] - The net cash flow from operating activities for the period was ¥156,542,251.09, a decrease of 3.9% compared to ¥162,837,035.03 in the previous period[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,865,231,270.92, a decrease of 4.08% compared to the end of the previous year[9] - The company's total assets amounted to CNY 2,724,791,030.04, slightly up from CNY 2,711,411,663.43 in the previous period[41] - Total liabilities decreased to CNY 763,556,434.79 from CNY 765,851,235.65[41] - The total equity of the company increased to CNY 1,961,234,595.25 from CNY 1,945,560,427.78[41] - Total current assets amounted to CNY 793,301,709.00, with cash and cash equivalents at CNY 61,407,367.72 and accounts receivable at CNY 118,813,861.65[71] - Total non-current assets reached CNY 1,918,109,954.43, including long-term receivables of CNY 595,779,233.74 and long-term equity investments of CNY 695,535,959.75[71] - Total liabilities were CNY 765,851,235.65, indicating a manageable debt level relative to assets[72] - Total equity reached CNY 1,945,560,427.78, with retained earnings of CNY 643,825,946.90[73] Shareholder Information - The total number of shareholders at the end of the reporting period was 13,487[13] - The largest shareholder, Shandong Runxin Investment Co., Ltd., held 36.93% of the shares, totaling 39,802,720 shares[13] Expenses and Costs - Sales expenses increased by 108.39% to CNY 12,225,192.85, mainly due to the acquisition of Italian Lisapharma, which expanded the scope of consolidation[21] - Total operating costs increased to CNY 248,450,361.33 from CNY 187,633,553.92, with operating costs specifically rising from CNY 142,043,637.39 to CNY 196,313,382.86[44] - The company reported a decrease in research and development expenses from CNY 11,711,583.82 to CNY 8,231,424.38[44] - Research and development expenses decreased to $25.05 million from $30.95 million, a reduction of 19.1%[52] Government Subsidies - The company received government subsidies amounting to CNY 13,293,017.47 related to its daily operations[10] - Other income surged by 305.17% to CNY 13,293,017.47, attributed to increased government subsidies related to daily operations[21] Financial Commitments - The company has no significant commitments or overdue promises from shareholders or related parties during the reporting period[25] - There were no instances of non-compliance regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[29][30] Future Outlook - The company expects an annual loss due to the renovation project for the new streptomycin, with an estimated scrapped equipment value of approximately CNY 15 million and idle equipment value of about CNY 13 million, pending final audit confirmation[27] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[74] - The company continues to focus on expanding its market presence and enhancing product development strategies[75]